Glenmark Pharmaceuticals is gearing up to introduce a groundbreaking cancer drug, Brukinsa (zanubrutinib), in India after receiving approval from the Drugs Controller General of India (DCGI). This significant development marks a new chapter in the treatment of B-cell blood cancers, offering Indian patients access to a global innovation with fewer heart-related side effects and convenient dosing.
Brukinsa, originally developed by the global oncology firm now known as BeOne Medicines, is the first Bruton’s tyrosine kinase (BTK) inhibitor approved in India for treating five forms of B-cell malignancies. These include chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL).
The medicine is an oral small-molecule that precisely targets and blocks the BTK protein responsible for the growth of cancerous B cells. What sets Brukinsa apart is its ability to deliver consistent inhibition with high bioavailability, while allowing the flexibility of once- or twice-daily dosage depending on the patient’s clinical needs.
More than 100,000 patients across the world have already been treated with Brukinsa. With over 6,000 participants involved in 35 clinical trials conducted in 30 countries, the drug has built a solid reputation for effectiveness and safety. In the landmark ALPINE trial for relapsed or hard-to-treat CLL patients, Brukinsa demonstrated a far lower incidence of major cardiac events—only 1.9 percent, compared to 7.7 percent seen with ibrutinib.
Glenmark is confident in the potential of Brukinsa to elevate cancer care in India. “We look forward to bringing BRUKINSA to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines),” said Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals.
While the exact launch timeline remains under wraps, the anticipation around this innovative therapy is rising. Glenmark’s recent expansions, including its cardiometabolic drug offerings, show a clear commitment to transforming healthcare options in India.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter |The Mainstream formerly known as CIO News Whatsapp Channel | The Mainstream formerly known as CIO News Instagram
About us:
The Mainstream formerly known as CIO News is a premier platform dedicated to delivering latest news, updates, and insights from the tech industry. With its strong foundation of intellectual property and thought leadership, the platform is well-positioned to stay ahead of the curve and lead conversations about how technology shapes our world. From its early days as CIO News to its rebranding as The Mainstream on November 28, 2024, it has been expanding its global reach, targeting key markets in the Middle East & Africa, ASEAN, the USA, and the UK. The Mainstream is a vision to put technology at the center of every conversation, inspiring professionals and organizations to embrace the future of tech.
